Aplastic Anemia - Pipeline Review, H1 2017

  • ID: 4267379
  • Report
  • 79 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • 3SBio Inc
  • Acceleron Pharma Inc
  • Amgen Inc
  • BioLineRx Ltd
  • F. Hoffmann-La Roche Ltd
  • Gamida Cell Ltd
  • MORE
Aplastic Anemia - Pipeline Review, H1 2017

Summary:

The latest Pharmaceutical and Healthcare disease pipeline guide Aplastic Anemia - Pipeline Review, H1 2017, provides an overview of the Aplastic Anemia (Hematological Disorders) pipeline landscape.

Aplastic anemia is a syndrome of bone marrow failure characterized by peripheral pancytopenia and marrow hypoplasia. Symptoms include fatigue, pale skin, rapid or irregular heart rate, shortness of breath with exertion, nosebleeds and bleeding gums, prolonged bleeding from cuts, skin rash, dizziness and headache. Risk factors include exposure to toxic chemicals, treatment with high-dose radiation or chemotherapy for cancer, certain blood diseases, autoimmune disorders and serious infections. Treatment includes immunosuppressants and stem cell transplant.

Report Highlights:

The latest Pharmaceutical and Healthcare latest pipeline guide Aplastic Anemia - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Aplastic Anemia (Hematological Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Aplastic Anemia (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Aplastic Anemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 2, 2, 1, 1 and 5 respectively.

Aplastic Anemia (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

- The pipeline guide provides a snapshot of the global therapeutic landscape of Aplastic Anemia (Hematological Disorders).
- The pipeline guide reviews pipeline therapeutics for Aplastic Anemia (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Aplastic Anemia (Hematological Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Aplastic Anemia (Hematological Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Aplastic Anemia (Hematological Disorders)

Reasons to Buy:

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Aplastic Anemia (Hematological Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Aplastic Anemia (Hematological Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • 3SBio Inc
  • Acceleron Pharma Inc
  • Amgen Inc
  • BioLineRx Ltd
  • F. Hoffmann-La Roche Ltd
  • Gamida Cell Ltd
  • MORE
Introduction

Aplastic Anemia - Overview

Aplastic Anemia - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Aplastic Anemia - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Aplastic Anemia - Companies Involved in Therapeutics Development

3SBio Inc

Acceleron Pharma Inc

Amgen Inc

BioLineRx Ltd

F. Hoffmann-La Roche Ltd

Gamida Cell Ltd

Novartis AG

Pluristem Therapeutics Inc

Regen BioPharma Inc

Aplastic Anemia - Drug Profiles

Anemir - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BL-8040 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cell Therapy for Aplastic Anemia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CordIn - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

eltrombopag olamine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Activate Telomerase for Aplastic Anemia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HemaXellerate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PLXR-18 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

romiplostim - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sotatercept - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

thrombopoietin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Aplastic Anemia - Dormant Projects

Aplastic Anemia - Discontinued Products

Aplastic Anemia - Product Development Milestones

Featured News & Press Releases

Apr 20, 2017: NIH study in NEJM shows Novartis drug eltrombopag as first-line therapy with standard treatment improves responses in severe aplastic anemia

Oct 24, 2016: Pan Am Cancer Treatment Center Provides Final HemaXellerate Clinical Data to Regen BioPharma, for treatment of Bone Marrow Suppression Study

Sep 22, 2016: Regen BioPharma Responds to FDA Comments on Its Application for Orphan Drug Designation on its Aplastic Anemia Therapy

Aug 25, 2016: Health Canada issues advisory on REVOLADE citing risk of severe hepatotoxicity

May 11, 2016: Regen BioPharma Discusses Recent Developments in Aplastic Anemia Therapy and Future Potential Expansion of HemaXellerate

May 03, 2016: Regen BioPharma Receives Preliminary Clinical Data from Pan Am Cancer Center Regarding Their HemaXellerate Study in Cancer Patients

Jan 26, 2016: Regen BioPharma Submits Application to FDA for Orphan Drug Designation for its HemaXellerate Product

Dec 15, 2015: Regen BioPharma Receives FDA Clearance to Initiate Clinical Trial of HemaXellerate

Nov 23, 2015: BioLineRx Announces Initiation of Phase 1/2 Trial for Novel Treatment in Two Bone Marrow Failure Conditions

Nov 17, 2015: Regen BioPharma Submits Response to FDA Questions on HemaXellerate Investigational New Drug Application

Nov 17, 2015: Pluristem to Present New Data on PLX-R18 at American Society of Hematology’s Annual Meeting

Sep 25, 2015: Regen BioPharma Announces Positive Results from GLP Safety Study for HemaXellerate

Sep 10, 2015: BioLineRx Announces Regulatory Submission for Phase 2 Trial of BL-8040 as Novel Treatment for Hypoplastic Myelodysplastic Syndrome and Aplastic Anemia

Sep 02, 2015: Novartis receives EU approval for new Revolade use as first-in-class therapy for patients with severe aplastic anemia

Jul 24, 2015: Novartis drug Revolade recommended by CHMP for EU approval to treat patients with severe aplastic anemia, a serious blood disorder

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables:

Number of Products under Development for Aplastic Anemia, H1

Number of Products under Development by Companies, H1

Products under Development by Companies, H1

Number of Products by Stage and Target, H1

Number of Products by Stage and Mechanism of Action, H1

Number of Products by Stage and Route of Administration, H1

Number of Products by Stage and Molecule Type, H1

Aplastic Anemia - Pipeline by 3SBio Inc, H1

Aplastic Anemia - Pipeline by Acceleron Pharma Inc, H1

Aplastic Anemia - Pipeline by Amgen Inc, H1

Aplastic Anemia - Pipeline by BioLineRx Ltd, H1

Aplastic Anemia - Pipeline by F. Hoffmann-La Roche Ltd, H1

Aplastic Anemia - Pipeline by Gamida Cell Ltd, H1

Aplastic Anemia - Pipeline by Novartis AG, H1

Aplastic Anemia - Pipeline by Pluristem Therapeutics Inc, H1

Aplastic Anemia - Pipeline by Regen BioPharma Inc, H1

Aplastic Anemia - Dormant Projects, H1

Aplastic Anemia - Discontinued Products, H1

List of Figures:

Number of Products under Development for Aplastic Anemia, H1

Number of Products under Development by Companies, H1

Number of Products by Targets, H1

Number of Products by Stage and Targets, H1

Number of Products by Mechanism of Actions, H1

Number of Products by Stage and Mechanism of Actions, H1

Number of Products by Routes of Administration, H1

Number of Products by Stage and Routes of Administration, H1

Number of Products by Molecule Types, H1

Number of Products by Stage and Molecule Types, H
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • 3SBio Inc
  • Acceleron Pharma Inc
  • Amgen Inc
  • BioLineRx Ltd
  • F. Hoffmann-La Roche Ltd
  • Gamida Cell Ltd
  • Novartis AG
  • Pluristem Therapeutics Inc
  • Regen BioPharma Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll